# CCTA-afgeleide FFR: prognostische waarde — meta-analyse

*geplaatst 2022-02-01 · Algemeen · Heart (British Cardiac Society) · doi 10.1136/heartjnl-2021-319773 · https://hartvaat.nl/2022/02/01/ccta-afgeleide-ffr-prognostische-waarde-meta-analyse/*

Systematische review en meta-analyse naar de prognostische waarde van CT-afgeleide fractional flow reserve.

## English: Prognostic value of coronary computed tomography angiographic derived fractional flow reserve: a systematic review and meta-analysis.

This meta-analysis evaluated the prognostic value of CT-derived fractional flow reserve (FFR-CT), showing that non-invasive physiological assessment of coronary stenoses predicts future cardiovascular events beyond anatomical assessment alone.

## Abstract (original, from the publication)

OBJECTIVES: To obtain more powerful assessment of the prognostic value of fractional flow reserveCT testing we performed a systematic literature review and collaborative meta-analysis of studies that assessed clinical outcomes of CT-derived calculation of FFR (FFRCT) (HeartFlow) analysis in patients with stable coronary artery disease (CAD). METHODS: We searched PubMed and Web of Science electronic databases for published studies that evaluated clinical outcomes following fractional flow reserveCT testing between 1 January 2010 and 31 December 2020. The primary endpoint was defined as 'all-cause mortality (ACM) or myocardial infarction (MI)' at 12-month follow-up. Exploratory analyses were performed using major adverse cardiovascular events (MACEs, ACM+MI+unplanned revascularisation), ACM, MI, spontaneous MI or unplanned (>3 months) revascularisation as the endpoint. RESULTS: Five studies were identified including a total of 5460 patients eligible for meta-analyses. The primary endpoint occurred in 60 (1.1%) patients, 0.6% (13/2126) with FFRCT>0.80% and 1.4% (47/3334) with FFRCT ≤0.80 (relative risk (RR) 2.31 (95% CI 1.29 to 4.13), p=0.005). Likewise, MACE, MI, spontaneous MI or unplanned revascularisation occurred more frequently in patients with FFRCT ≤0.80 versus patients with FFRCT >0.80. Each 0.10-unit FFRCT reduction was associated with a greater risk of the primary endpoint (RR 1.67 (95% CI 1.47 to 1.87), p<0.001). CONCLUSIONS: The 12-month outcomes in patients with stable CAD show low rates of events in those with a negative FFRCT result, and lower risk of an unfavourable outcome in patients with a negative test result compared with patients with a positive test result. Moreover, the FFRCT numerical value was inversely associated with outcomes.

Auteurs: Bjarne L Nørgaard, Sara Gaur, Timothy A Fairbairn, Pam S Douglas, Jesper M Jensen, Manesh R Patel, Abdul R Ihdayhid, Brian S H Ko, Stephanie L Sellers, Jonathan Weir-McCall, Hitoshi Matsuo, Niels Peter R Sand, Kristian A Øvrehus, Campbell Rogers, Sarah Mullen, Koen Nieman, Erik Parner, Jonathon Leipsic, Jawdat Abdulla

---
Bron: Heart (British Cardiac Society), https://doi.org/10.1136/heartjnl-2021-319773. Bijgewerkt 2026-07-03T13:28:43Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.